# 1. Financial Performance ## A. Key Figures * **Revenue:** **₹439 Cr** Q4 (+30%) · **₹1,549 Cr** FY26 (+18%) * **EBITDA:** **₹121 Cr** Q4 (+40%) · **₹445 Cr** FY26 (+30%) * **Margins:** **29%** FY26 EBITDA Margin (+300 bps) · **70%** FY26 Gross Margin * **Adjusted PAT:** **₹87 Cr** Q4 · **₹232 Cr** FY26 (+135%) * **ROCE (Adjusted):** **17.4%** FY26 (vs. 4% in FY23) * **Debt & Capex:** **₹613 Cr** Net Debt · **₹361 Cr** FY26 Capex ## B. Revenue & Profitability Trends * **Record Top-line Performance:** Achieved highest-ever quarterly and annual revenues, with the core base business (excluding licensing) delivering exceptional high double-digit growth. * **Operating Leverage & Margin Expansion:** Record EBITDA levels and significant annual margin improvement driven by key vertical performance and enhanced manufacturing utilization. * **Platform Monetization:** Early-stage commercialization of technology platforms is expected to drive sustainable growth and further strengthen return ratios. ## C. Capital Efficiency & Returns * **Significant ROCE Accretion:** Adjusted return on capital saw a sharp multi-year recovery, though this figure excludes capital intensive investments in **biologics and New Biological Entities (NBE)**. * **Asset Base:** The company’s gross block has reached **₹2,281 Cr**, reflecting substantial historical investment in specialized capabilities. ## D. Debt & Future Outlay * **Capex Discipline:** Future capital expenditure is projected to remain flat year-on-year, with a focus on API, CDMO, and albumin facilities. * **Funding & Liquidity:** While net debt saw a moderate increase, interest expenses have stabilized; management intends to fund upcoming requirements through internal accruals. --- # 2. Product & Pipeline Performance ## A. Key Figures * **Biologics Revenue:** **₹150 Cr** FY26 (+100%) * **Oncology Pipeline:** **15+ New Products** targeting blockbusters through 2032 ## B. Oncology and Generics * **Strategic Pipeline Expansion:** Robust growth in generic oncology targeting long-term patent expiries; key exhibit and registration batches for **Abraxane** and **Enzalutamide** completed with launches targeted for **FY28**. * **GLP-1 Positioning:** Completed validation of **Semaglutide** with DMF readiness expected in **H1 2027**; competitive edge derived from dual synthetic/semisynthetic API capabilities and in-house formulation. * **Complex Generics:** **Rotigotine transdermal patch** set for near-term European launch, with significant commercial scaling anticipated in **FY28**. ## C. Biologics and Biosimilars * **Hyper-Growth in Biologics:** Segment revenue doubled year-on-year, catalyzed by strong CDMO deal momentum and milestone payments. * **Clinical Milestones:** **Aflibercept** remains on track for **FY27** launch; **Nivolumab** and two **New Biological Entities (NBE)** are transitioning to human clinical studies within the current fiscal year. * **Albumin Program:** Received CDSCO approval for Global Phase III studies for recombinant human albumin; regulatory filings in Europe (IMPD) scheduled for **H1 FY27**. * **Market Selectivity:** Management is bypassing a European launch for **Aflibercept** due to prohibitive clinical costs and late-entry risks, unless a funding partner is secured. ## D. Novel 505(b)(2) Products * **NCE Momentum:** **NorUDCA** (first NCE) demonstrating strong domestic uptake and a healthy order book; global human studies in the U.S. and Europe slated for **FY27**. * **Complex Injectables:** **Ondansetron extended-release** launch expected in India in **FY27**, supported by a confidential IP strategy to navigate global patent landscapes. * **Portfolio Rationalization:** Discontinued the **Green Tea Film** product to focus resources on high-value clinical programs like **SMLTOP09** for androgenic alopecia. ## E. Specialty Technology Platforms * **ADC Leadership:** Completed development of the first **ADC biosimilar** with human trials starting in **FY27**; development of a second ADC asset is already underway. * **Polymer Business:** Segment is now commercialized with one active product; management expects steady growth contribution from this platform over the long term. --- # 3. Segment & Geography Mix ## A. Key Figures * **API Revenue:** **₹259 Cr** Quarterly (+16%) · **₹985 Cr** Full Year (+16%) * **Formulation Revenue:** **₹205 Cr** Quarterly (+54%) · **₹618 Cr** Full Year (+30%) * **European Formulation Revenue:** **>₹200 Cr** Full Year (>+100%) * **B. S. Formulation Revenue:** **₹80 Cr** Full Year (vs. ₹54 Cr FY25) * **CDMO Revenue Contribution:** **~₹110 Cr** from API segment · **~₹110 Cr** from Biologics ## B. API and Formulations * **Strategic Pivot:** Transitioned into a differentiated platform focusing on complex APIs, biologics, and ADCs, resulting in a balanced **50/50** revenue split between API and higher-value Formulation/Biologics segments. * **Import Substitution Success:** Completed process validation for a non-oncology import substitute and received **CEP** for Methotrexate, strengthening the oncology API portfolio. * **Vertical Integration:** Oncology API growth is being prioritized for captive consumption (backward integration) to maximize realizations through non-infringing formulation launches. * **High-Value Pipeline:** Targeting the large **Semaglutide** market and the supply-constrained **recombinant albumin** market to drive future domestic and global volumes. ## C. CDMO Program Momentum * **NCE Commercialization:** Successfully launched the first U.S. NCE program with a big pharma partner; currently supplying API for a second program in **Phase III** trials. * **Pipeline Expansion:** Managing **five active programs**, including an innovator project with Phase I clinical batches initiated; two additional NCE programs completed audits for **FY27** revenue starts. * **Monetization Outlook:** Management anticipates substantial licensing income from biosimilars in Europe and ROW markets during the upcoming fiscal year. ## D. European & U.S. Market Scaling * **European Hyper-growth:** Triple-digit revenue surge driven by niche product launches; **7 new products** (including Tadalafil film) are slated for launch in **FY27**. --- # 4. Manufacturing & Capacity ## A. Facility Utilization & Global Compliance * **Operational Resilience:** The **Jadcherla formulation facility** maintains high utilization rates despite pending U.S. FDA status, supported by active accreditations from **Europe, Latin America, and Saudi Arabia**. * **Strategic R&D Prioritization:** Management is focusing reinvestment on projects with **near-to-mid-term revenue potential**, intentionally pivoting away from long-gestation investments to protect EBITDA margins. ## B. New Block Commissioning & Expansion * **Oncology & Peptide Scaling:** Capacity expansion is underway with a new oncology API block and a large-scale peptide manufacturing block (equipment ordered) both slated for **FY27** commissioning. * **Pipeline Readiness:** The oncology expansion will support the development of **15-plus new oncology APIs**, while OLC approval is anticipated in **FY27** following Q4 FY26 block commissioning. * **Albumin Timeline Shift:** IMPD submission for albumin has been rescheduled to **H1 FY27** to align with the completion of validation batches at the new facility. ## C. Integrated ADC Suite * **End-to-End Capabilities:** The company is establishing a unique, integrated ADC suite in India, providing a single-facility solution for mAbs, payloads, linkers, and conjugation. * **Commercial Validation:** Supply of payloads and linkers is already active, with a major pharmaceutical client expected to complete registration batches using Shilpa’s payload in **Q4 FY26**. --- # 5. M&A & Partnerships ## A. Key Figures * **Exceptional Gain:** **₹30 Cr** from Sravathi Advance stake sale * **Associate Profit Share:** **₹18 Cr** from Maaia (35% stake) ## B. Strategic Licensing Deals * **Biologics Monetization:** Out-licensed Aflibercept for India and Russia; management expects licensing income to surpass previous Adalimumab benchmarks. * **Milestone Visibility:** Significant payments anticipated within the current fiscal year, contingent on product launch and one-year performance markers. * **Asset Strategy:** Maintaining a "wait-and-see" approach for SMLTOP09, deferring partnership talks until **Phase III data** is finalized to maximize value. * **Revenue Classification:** Licensing fee line items are strictly limited to pure product licensing, excluding any CDMO-related contributions. ## C. Innovator CDMO Collaborations * **NCE Pipeline Momentum:** Progressing a third U.S. NCE program with Unicycive Therapeutics; regulatory submissions for both API and formulation are finalized. * **Clinical Timelines:** Partnered programs with mAbTree Biologics and Alveolus Bio are slated to commence human clinical trials in **FY27**. * **Long-term Oncology Outlook:** Servicing an innovator breakthrough molecule with expected meaningful revenue contribution by **FY28**, though not projected to reach historical peak levels. ## D. Associate Entity Performance * **Strategic Divestment:** Realized a significant gain following the partial sale of Sravathi Advance, resulting in its reclassification from a JV to an associate company. * **Maaia Turnaround:** Reported a notable profit share from Maaia, leading to the reinstatement of investment value previously written down to zero due to R&D losses. ## E. Global Distribution Partners * **Geographic Expansion:** Initiated LatAm market entry for the biologics portfolio by partnering Nivolumab with SteinCares. * **Commercial Execution:** Domestic success for novel products (NorUDCA, Ondansetron) remains tethered to the distribution capabilities of strategic partners. * **Semaglutide Strategy:** Export-led model established for Semaglutide, focusing on direct API supply while leveraging regional partners for formulation distribution. --- # 6. Pricing & Regulatory Risks ## A. Regulatory & Audit Status * **Facility Resilience:** The **Jadcherla facility** is awaiting a U.S. FDA reaudit following observations; however, management confirms no revenue impact as U.S. production is currently insulated via **third-party CMO sites**. * **Clinical Trial Progress:** Phase III global trials for **SMLTOP09** (topical dutasteride) are resuming following the completion of additional preclinical data requested by regulators. * **European Compliance:** Complex product submissions in Europe now necessitate **local patient data**, adding a specific geographic requirement to study protocols. * **Domestic Hurdles:** The India launch of **Tranexamic Acid spray** remains stalled as the company navigates ongoing government regulatory frameworks. ## B. Market Dynamics & Competition * **Generic Entry Timing:** Nilotinib faces generic competition in Europe this fiscal year, though tender cycles of **1 to 2 years** will likely delay significant value erosion until **FY28**. * **Pipeline Strategy:** Management is pivoting away from low-potential genericized products, focusing instead on **high-value assets** with future patent expiries. * **Supply Chain Inflation:** While raw material and solvent availability remains stable, the business is currently absorbing **significant price increases** in input costs. ## C. Future Outlook * **Revenue Contribution:** Management signaled a conservative outlook for **OLC**, anticipating no meaningful financial impact in **FY27** due to confidential approval timelines. * **Approval Lead Times:** Regulatory clearance for clinical trials is currently trending at a **3 to 4 month** window following IMPD submission. --- # 7. Guidance & Outlook ## A. Key Figures * **EBITDA Margin:** **29%** Current FY · **35%** Long-term Target * Licensing & Service Income: ~₹200 Cr in FY26, expected to remain in similar range in FY27 ## B. FY27 Revenue Triggers * **Formulation Momentum:** Anticipated significant growth driven by existing portfolios and a high-value pipeline of **differentiated 505(b)(2) products**. * **Product Launch Visibility:** NorUDCA volume clarity expected by **Q2** following its November launch; Nilotinib is projected to reach full market potential by next year via **ROW market** expansion. * **Regulatory De-risking:** Secured European scientific advice for recombinant albumin, approving clinical designs and removing the need for additional studies prior to expected **FY29** revenues. * **Income Stability:** Licensing and service revenue expected to remain consistent with current levels, supported by a robust deal pipeline and visibility. ## C. Long-term Biologics Roadmap * **Sequential Launch Pipeline:** Biologics growth anchored by the anticipated launch of **Aflibercept** in **H2 FY27**, followed by **Nivolumab** and **Pembrolizumab** in **late FY28**. * **Asset Monetization:** Strategy centers on monetizing biologic assets to sustain a high growth trajectory, targeting **40% to 50%** growth projections. ## D. Profitability & Scale * **Margin Expansion:** Management targeting a significant step-up in EBITDA margins through operational leverage, though near-term gains are balanced against scaling costs. * **Strategic Scaling:** Commitment to year-over-year growth within the affordable healthcare sector, with significant scaling opportunities expected to materialize starting in **FY27**.